Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hyunseong Yu
Institution:
Celltrion (South Korea)
Observed institutions:
Seoul National University,
Celltrion (South Korea)
ORCID:
0009-0005-6954-983X
Observed ORCID:
0009-0005-6954-983X
OpenAlex ID:
A5111328915
NADPH oxidase 1/4 dual inhibitor setanaxib suppresses platelet activation and thrombus formation
2024
·
Eun Bee Oh
, Hye Ji Shin
, et al.
·
Life Sciences
·
12
Targeting NADPH Oxidase with APX-115: Suppression of Platelet Activation and Thrombotic Response
2025
·
Joara Jang
, Hyunseong Yu
, et al.
·
Antioxidants and Redox Signaling
·
11
PDF
NADPH oxidase 2 inhibitor GSK2795039 exerts antiplatelet and antithrombotic activity
2025
·
Eun Bee Oh
, Yun Jeong Kong
, et al.
·
Scientific Reports
·
5
PDF
Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials
2026
·
Marla C Dubinsky
, Stefan Schreiber
, et al.
·
Inflammatory Bowel Diseases
·
1
Pharmacokinetics and efficacy of subcutaneous infliximab 120 mg every 2 weeks: a post hoc comparison with intravenous dosing in a phase 1 study in patients with inflammatory bowel disease.
2026
·
Stefan Schreiber
, Byong Duk Ye
, et al.
·
PubMed Central
PDF
Su1847: TIME TO CLINICAL RECAPTURE AFTER DOSE ESCALATION OF SUBCUTANEOUS INFLIXIMAB FOLLOWING LOSS OF RESPONSE: A POST HOC ANALYSIS OF THE 2-YEAR PHASE 3 LIBERTY-CD & LIBERTY-UC TRIALS
2025
·
Marla Dubinsky
, Stefan Schreiber
, et al.
·
Gastroenterology
Show more works
View as search
Works count:
6
Citation count:
29
H-index:
3
I10-index:
2
Year
Topic
Type
